Login to Your Account



POSITIVE PHASE III DATA REPORTED

Sinovac Biotech takes aim at health scourge HFMD with enterovirus vaccine

By Cornelia Zou
Staff Writer

Wednesday, March 26, 2014

HONG KONG – Vaccine maker Sinovac Biotech Ltd.’s positive results from a phase III clinical trial for its enterovirus 71 (EV71) vaccine for hand, foot and mouth disease (HFMD) are welcome news in China since HFMD has emerged as a health scourge in China.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription